<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IDOXURIDINE (IDU)</span><br/>(eye-dox-yoor'i-deen)<br/><span class="topboxtradename">Herplex Liquifilm, </span><span class="topboxtradename">IDU, </span><span class="topboxtradename">Stoxil<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Acyclovir<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.1% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>Topical antiviral agent. Pyrimidine nucleoside structurally related to thymidine, a nucleic acid essential for synthesis of
         viral DNA. Antiviral activity is primarily due to inhibition of viral replication.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits growth of <i>Herpes simplex types I</i> and <i>II, varicella-zoster, vaccinia, cytomegalovirus,</i> and small animal viruses containing DNA. Not effective against RNA viruses. Epithelial viral infections characterized by
         a dendritic figure respond well to the antiviral activity especially during initial attacks. Chronic or recurrent viral infections
         that involve deep stromal structures (e.g., herpetic iritis) respond less well and do not heal. Some resistant strains of
         <i>Herpes simplex</i> have been reported.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>
<i>Herpes simplex</i> keratitis as single agent or conjunctively with a corticosteroid.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Cutaneous <i>Herpes simplex.</i>
</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to idoxuridine, iodine or iodine-containing preparations, or any components in the formulation, lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C), corticosteroid therapy.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Herpes Simplex Keratitis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">Topical</span> 1 drop instilled in conjunctival sac q1h during the day and q2h at night until improvement occurs, then decrease to q2h during
               the day and q4h at night; use ointment q4h during the day with the last dose at bedtime (5 applications/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Prevent the possibility of systemic absorption by applying light finger pressure to head of lacrimal duct for 1 min when eyedrop
            is instilled.
         </li>
<li>Follow manufacturer's directions regarding storage. Decomposed idoxuridine not only has reduced antiviral activity but also
            may be toxic.
         </li>
<li>Store ophthalmic solution refrigerated at 2°8° C (36°46° F) in a tight, light-resistant container
            unless otherwise directed. The ointment should be stored at 2°15° C (36°59° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Sensitization, systemic absorption (stomatitis, anorexia, nausea, vomiting, alopecia, leukopenia, thrombocytopenia, iodism,
      hepatotoxicity). <span class="typehead">Special Senses:</span> Local irritation, pain, burning, lacrimation, pruritus, inflammation, or edema of eyes, lids, and surrounding face; follicular
      conjunctivitis, photophobia; corneal ulceration and swelling; delayed healing, small defects in corneal epithelium (local
      overdosage). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Boric acid</b>-containing solutions may cause precipitation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from eye tissues. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness. Epithelial infections usually improve within 78 d. If patient continues to improve,
            therapy is generally continued <img src="../images/special/lesserorequal.gif"/>21 d.
         </li>
<li>Supervise patients closely by ophthalmologist.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn proper technique for eye drop instillation.</li>
<li>Do not exceed the recommended frequency and duration of therapy.</li>
<li>Wear sunglasses if photosensitivity is troublesome.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>